Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1484)	10/24/2002 1:57:00 PM
From: scaram(o)uche	Respond to of 2243

Tuck: I don't often resent someone like I resent Mr. Dr. Pres., R&D at MEDI. If you look hard enough, you can find immunogenicity for most (all?) human or humanized antibodies. In this case, I believe that MEDI has not only looked hard, but is also using related verbiage to "face save". They are finally, IMO, going to test the antibody as it should have been tested....... at doses that do not deplete T cells apart from those exposed to antigen in the course of ongoing autoimmunity. Hand waving! At least three years and many millions, wasted. Will MEDI look this hard for (non-neutralizing) antibody responses to vitaxin? If they find (non-neutralizing) antibodies to vitaxin, will they (1) go out of their way to publicize their presence, (2) posture that FDA gives a damn, and (3) redesign trials to do an antibody run-around? No!!!!!!!!!! This just extends a long-standing issue at MEDI, IMO....... communications are designed to hide deficiencies re. R&D foresight and management. What will happen if the new trials, at non-depleting doses, are successful? Mr. Dr. Pres., R&D will claim that he discovered a wonderful new route for using 507. Bet on it. Rick

To: tuck who wrote (1484)	10/24/2002 2:22:30 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 2243

>> If so, maybe BTRN would be a buy if/when MEDI goes that way, or if they return the rights to BTRN and BTRN goes that way << I never addressed your major point..... sure, but that's a long way off. I think that BTRN should determine what serological responses to vitaxin look like in MEDI's hands. Let's not forget that MEDI humanized the antibody. And why is this shocking (not!) immunogenicity just now -- after such an extended period of human testing -- coming to light?